Targeting the PI3K pathway in cancer: are we making headway?

By F. Janku, T. Yap, Funda Meric-Bernstam. Nature Reviews Clinical Oncology, 2018

921 citations recorded by the source corpus.

Subfields: Molecular Biology, Pulmonary and Respiratory Medicine

View Paper: https://www.semanticscholar.org/paper/a5d5775d0494f9efde4b0acfb61ad380423f2757

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Molecular Biology

1. Abel Gonzalez-Perez
2. Núria López-Bigas
3. Nikolaus Schultz
4. Charles Swanton
5. Gautam Sethi
6. G. Tortora
7. D. Fruman
8. Abhishek Niroula

In Pulmonary and Respiratory Medicine

1. Charles Swanton

Citations in the corpus

• A framework to rank genomic alterations as targets for cancer precision medicine: the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT) (2018, background): “However, the responses did not impact outcome [38].”
• PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer (2023, background): “The most common grade 3–4 treatment-emergent adverse event after combination of everolimus and lenvatinib in RCC patients are constipation (37%) and diarrhea (20%) [4, 292].”